Constellation owns the perpetual U.S. import rights to Modelo, Corona, and Pacifico, a beer portfolio with structural growth and pricing power. At $152.82 versus a base IV of $368.64, the stock trades at 0.41x intrinsic value with a reverse-DCF implying just 2.6% growth.

Plain English

Constellation Brands owns the U.S. rights to sell Corona, Modelo, and Pacifico beer — they import it from Mexico and sell it through American beer distributors. Modelo Especial is now the best-selling beer in America. They make about $1.4 billion in cash every year from this. They also own a wine business that's not very good and they're selling pieces of it off. The stock is at $153 and we think the business is worth roughly $370 a share — about 2.4 times what you pay today. The catch: Mexican tariffs and weight-loss drugs could hurt them.

Thesis

Constellation Brands is two businesses bolted together. The first, U.S. import beer (~85% of EBIT and growing), holds the perpetual, royalty-free U.S. rights to Modelo Especial, Corona, Pacifico, and Victoria, sold through a hardened three-tier distributor network. Modelo Especial is the #1 selling beer in America by dollars, and the portfolio has compounded depletions in the high single digits for over a decade — secular share gains funded by Hispanic demographic tailwinds and category mix shift. The second, Wine & Spirits, is a diluting commodity-like business that management is actively shrinking via the 2025 divestitures.

The scorecard tells the story: 10-year average ROIC of 9.55%, FCF conversion of 89.9%, owner earnings TTM of $1.43B, leverage at 2.83x net debt / EBITDA. Composite is 71. Profitability (18) and capital allocation (18) are good, balance sheet (14) reflects the leverage from 2013's $4.75B Crown Imports buyout and ongoing brewery capex in Mexico, and valuation scores 21 of 25 — the cheapest leg of the thesis.

The price/IV math is what makes this interesting. At $152.82 against IV-low $250.50, IV-base $368.64, and IV-high $398.03, the px/IV ratio is 0.4146. The reverse DCF implies a perpetual growth rate of just 2.64% — below nominal GDP, below historical beer-segment depletion growth, and below management's own mid-single-digit guidance. Either the market is right that GLP-1s, tariffs, and Hispanic consumer weakness permanently impair the beer franchise, or this is a textbook Buffett setup: a wonderful business available at a fair-to-cheap price during a cyclical growth pause. I lean toward the latter, with eyes open.

Moat

Constellation's economic moat is concentrated almost entirely in one asset: the perpetual, exclusive, royalty-free U.S. distribution rights to Grupo Modelo's beer portfolio, acquired in 2013 from AB InBev as a DOJ-mandated divestiture. This is one of the more unusual and valuable franchise rights in American consumer staples. I'll work through all five moat sources.

1. Intangibles / Brand (WIDE). Modelo Especial, Corona Extra, Corona Premier, Pacifico, and Victoria are top-tier consumer brands with a combined ~10% U.S. beer market share by volume and rising share by dollars. Modelo Especial overtook Bud Light in 2023 as the best-selling beer in America by retail dollars. This is exactly the 'buy commodities, sell brands' formula Buffett describes [2] — Constellation buys barley, hops, water, and aluminum and sells a $1.50/can branded experience. Damodaran's framing applies cleanly: brand value 'is not the cause' of high ROIC, it 'is the consequence' of decades of relentless brand investment [1]. The Hispanic-American demographic is structurally favorable; Modelo's authenticity story (brewed in Mexico, imported, no domestic license) cannot be replicated by Bud or Coors.

2. Cost advantages / Regulatory (WIDE, but with a twist). The U.S. three-tier alcohol distribution system is a state-mandated regulatory moat that cuts both ways. Constellation does not own distribution; its independent distributors do, and they are protected by state franchise laws that make it nearly impossible to fire them. This means Constellation's brands receive priority shelf placement, cold-box space, and salesforce attention from distributors who depend on Modelo volume. A new entrant would need 50 separate state-by-state distributor relationships, and the existing distributors are full. The Mexican brewery footprint (Nava, Obregón, and the new Veracruz plant) provides cost advantages from scale, but capex has been heavy.

3. Pricing power (NARROW-to-WIDE). Constellation has taken 1-3% price every year for a decade and has not seen meaningful elasticity — Modelo drinkers do not down-trade to Tecate. However, this is consumer staples pricing, not Coca-Cola pricing; aggressive price hikes in 2024-25 did finally produce some volume softness, suggesting the brand can price ahead of inflation but not by 10%. Call this narrow pricing power that compounds.

4. Switching costs (NONE). Beer drinkers face zero switching costs at the case level. The moat operates one shelf-set up, at the distributor level, not at the consumer level.

5. Network effects (NONE). Not applicable to beer.

Competitor stress test ($10B + 5 years). If AB InBev or Heineken were handed $10B and five years and told to displace Modelo, they would fail. The DOJ-imposed perpetual license from the 2013 consent decree means AB InBev cannot re-enter Modelo distribution in the U.S. — even if they wanted to. Heineken would need to build a Hispanic-authenticity brand from scratch (Tecate already exists and has been outcompeted by Modelo for 20 years). A new craft entrant lacks distribution scale. The most credible threat is intra-Constellation brand cannibalization (Modelo eating Corona) and the slow secular decline in total beer consumption.

Erosion risks. (a) GLP-1 weight-loss drugs may permanently reduce per-capita alcohol consumption — early data suggests 10-30% reduction in alcohol intake among users; this is a real, novel risk Buffett never had to model. (b) Hispanic consumer weakness from immigration crackdowns and tariff-driven inflation directly hits Modelo's core demographic. (c) Mexican-brewery tariff risk: Trump-era 25% tariffs on Mexican imports would compress beer-segment margins by ~500-700 bps and cannot be fully passed through. (d) Wine & spirits is impaired and will likely be sold at a loss — this is a moatless business in secular decline.

Moat verdict: WIDE — but the wide moat applies to the beer segment only, not the consolidated entity. The wine business has no moat and is being divested.

Management

Bill Newlands has been CEO since 2019; Garth Hankinson is CFO. The Sands family (Richard and Robert) retains substantial Class B voting control and remains influential. Capital allocation is the right lens for Constellation because management makes one decision a year that matters: how to deploy ~$1.4-2.0B of owner earnings.

1. Reinvestment in the beer business — A. This has been the right call. Mexican brewery expansion (Nava expansions, Obregón build-out, and the new Veracruz facility currently under construction) has supported double-digit volume growth in beer for a decade. The capex is heavy and lumpy — current free cash flow is depressed by the Veracruz build — which is one reason the stock is cheap. The scorer flags 'maintenance capex uncertain (>50% spread)' precisely because growth capex is hard to separate from maintenance capex during build years. ROIC of 9.55% averaged over 10 years is fine for consumer staples; ROIC on the beer segment alone is materially higher (likely 15-20%+) and is masked by Wine & Spirits and goodwill from the original $4.75B Crown Imports purchase.

2. M&A — D, with one A+ exception. The 2013 Crown Imports transaction (buying out AB InBev's stake in the Modelo U.S. business) is one of the great consumer-staples deals of the 21st century — paid $4.75B for an asset now worth $40-50B. Everything else has been weaker: the 2017 Casa Noble tequila acquisition, the 2020 Empathy Wines deal, and most damagingly the $4B Canopy Growth (cannabis) investment in 2018 that has been written down to near zero. The Canopy investment is a Buffett-style 'diworsification' — outside circle of competence, regulatory roulette, and a complete capital write-off. Wine acquisitions have generally underperformed and are now being divested at a loss. Net: one transformational hit, several misses.

3. Debt — B-. Net debt / EBITDA of 2.83x is elevated for a consumer staples company; peers like Diageo and Brown-Forman run 2-3x and KO/PEP run 2-2.5x. The leverage is a legacy of the 2013 Modelo deal financing and ongoing brewery capex. Management has guided to a long-term target of 3.0x and is comfortable here. Interest coverage data is incomplete in the scorecard, but with investment-grade ratings (BBB) the debt is serviceable. This is leverage, not danger.

4. Buybacks — B+. Constellation has been an aggressive repurchaser. During FY2024-2026 the company has been buying back stock in the $200-260 range, accelerating below $200. At current $152.82 vs. base IV $368.64, repurchases are highly accretive. The scorer notes 'Net capital return period; ROIIC not meaningful' which confirms management is currently in shareholder-return mode rather than reinvestment mode. The risk is that buybacks above $250-300 in 2021-22 destroyed value relative to current prices, but the historical avg P/IV looks favorable in retrospect.

5. Dividends — B. The dividend yield is ~2.7%, payout ratio ~40%, with a multi-year track record of mid-single-digit dividend growth. Reasonable, not exceptional.

Communication quality — B. The investor day cadence is decent. Management has been honest about Wine & Spirits being broken and is divesting. They are honest about beer-segment volume softness in 2024-25. They were not honest enough, soon enough, about the Canopy Growth investment. The Sands family voting control means activist pressure has limited reach, which is a double-edged sword (long-termism vs. governance).

Capital allocator: B. One transformational deal, disciplined operational reinvestment, sensible buybacks at current prices, but a $4B cannabis crater and a serially mediocre wine M&A history pull the grade down from A.

Industry

Constellation operates in two industries: U.S. premium beer (the franchise) and global wine & spirits (the divestiture pile). Porter's Five Forces apply very differently to each.

Beer — U.S. premium imports.

1. Threat of new entrants — LOW. The U.S. three-tier distribution system is a regulatory moat: 50 state-by-state distributor relationships, franchise laws that protect distributors, and a saturated wholesaler base. Craft beer entrants have proliferated at the local level but cannot achieve national scale; the share of total beer held by craft has plateaued around 13% and is now declining. Importing a credible Mexican beer brand from scratch is essentially impossible — the established Mexican brewers (Modelo, Heineken-owned Tecate) own the authenticity narrative.

2. Bargaining power of suppliers — MODERATE. Aluminum cans, glass bottles, barley, and hops are commodity inputs with global pricing. Constellation owns its breweries, so the supplier relationship is mostly with materials providers. Mexican labor is cheap. The real supplier risk is geopolitical: any U.S. tariff on Mexican imports is functionally a supplier-cost shock.

3. Bargaining power of buyers — MODERATE. The buyer is the distributor, not the consumer. Distributors are regulatory-bound and cannot easily drop a top-selling brand, but consolidation among distributors (Reyes, Breakthru) gives the largest buyers some leverage. End consumers face a fragmented retail environment (grocery, c-store, on-premise) and have low switching costs at the brand level.

4. Threat of substitutes — RISING. This is the single most important Porter analysis for STZ in 2026. Substitutes include (a) hard seltzer / RTDs — peaked in 2021, now retreating; (b) cannabis — a real long-term category competitor where legal; (c) GLP-1-driven sobriety — a novel structural threat; (d) non-alcoholic beer — growing, with Heineken 0.0 and Athletic Brewing leading. Modelo has a smaller non-alc presence than peers. The scorer's reverse-DCF growth of 2.64% may already price these substitutes in.

5. Industry rivalry — MODERATE. AB InBev (Bud Light, Michelob Ultra), Molson Coors (Coors Light, Miller), Heineken (Heineken, Dos Equis, Tecate). The 2023 Bud Light boycott handed Constellation a one-time market-share gain that is now lapping. Day-to-day rivalry on price is restrained; rivalry on innovation and shelf space is intense. Modelo's #1 dollar-share position is durable but not unassailable.

Value pool location: The premium and super-premium tiers ($1.50+/can) hold the profit pool; economy beer is a low-margin race to the bottom. Constellation is overwhelmingly premium-positioned. Trajectory: The premium-beer profit pool is roughly flat-to-modestly-growing; share is shifting between players within it.

Wine & Spirits — much weaker industry. Premium wine has been in secular decline among Millennials and Gen-Z; spirits face GLP-1 and cannabis pressure; private-label wine erodes branded margins. The industry verdict for wine alone would be Average-to-Poor.

Industry Verdict: Good — for the consolidated entity, weighted toward beer where the structure is favorable. The beer segment alone would rate Excellent; the wine segment drags the consolidated verdict to Good.

Inversion

I am now a short-seller pitching STZ at $152.82.

The single event that kills this thesis. A 25%+ U.S. tariff on Mexican imports, applied to beer specifically, is the binary outcome that breaks Constellation. Unlike Diageo or Brown-Forman, Constellation cannot relocate production — its U.S. license requires the beer to be brewed in Mexico for authenticity, and the breweries themselves represent ~$10B of sunk capital in Nava, Obregón, and Veracruz. A 25% tariff cannot be fully passed through (Modelo is not Hermès) and would compress beer EBIT margins from ~38% toward ~28-30%, taking $1B+ off annual EBIT. Pair that with 2026-2028 election-cycle anti-Mexico rhetoric and this is not a tail risk — it is a 20-30% probability scenario the market is currently underweighting because tariff news is noisy.

Why the moat is narrower than bulls think. The bull thesis treats Modelo as Coca-Cola: timeless, global, infinitely durable. It is not. Modelo's moat is geographically confined to the United States (the rest of the world's Modelo rights are owned by AB InBev) and demographically tilted to Hispanic-American men, the consumer cohort most exposed to (a) immigration enforcement, (b) GLP-1 prescription rates rising fastest in working-class populations, and (c) cannabis legalization in core Modelo states (California, Texas, Arizona, Florida). The 'authenticity' moat is also a cage: Constellation cannot export Modelo abroad, cannot extend the brand into spirits without dilution, and cannot move production to avoid tariffs. The wine & spirits segment, meanwhile, has zero moat — the divestitures booked $1B+ in losses, confirming the assets were impaired for years.

Why management is worse than it appears. The Canopy Growth investment is the tell. Management deployed $4B of shareholder capital into a Canadian cannabis SPAC in 2018, when every sober investor in consumer staples was warning that Canadian cannabis was a regulatory disaster waiting to happen. The investment has been written down by ~95%. This is not a small mistake — it is $4B, or roughly 1.5 years of beer-segment EBIT, lit on fire. A management team capable of that mistake is capable of others. Wine acquisitions have a similar pattern: bought high, sold low. The Sands family's dual-class voting structure means shareholders cannot vote out management — Class B holders (the family) hold ~60% voting power with ~10% economic interest, which is a governance flag Buffett would not accept in a new investment. Insider-friendly Class B structures are correlated with poor capital allocation across the long run.

What bulls are extrapolating that won't hold. Bulls extrapolate (a) high-single-digit beer depletion growth into perpetuity; (b) ongoing Hispanic demographic tailwind; (c) Modelo's #1 dollar-share gains continuing post-Bud Light. All three are weakening simultaneously. Beer depletions in 2024-25 went negative for the first time in the post-2013 era; not by much, but the trend is unmistakable. The Hispanic demographic is still growing in absolute terms, but immigration policy under the current administration is deliberately suppressing it. The Bud Light gain was a one-time gift that AB InBev is now lapping with Michelob Ultra (which is also imported). And — the real killer — the youngest cohort, Gen Z, drinks 30-40% less alcohol per capita than Millennials did at the same age. Beer is not just facing GLP-1; it is facing a generational tee-totaling shift that no amount of Modelo marketing can reverse.

Valuation trap (multiple compression / regime change). P/E TTM of 15.23 is barely below the 10-year average of 15.73 — which means the multiple has not actually compressed; what has compressed is forward-earnings expectations. EV/FCF of 24.16 is HIGH, not low, reflecting depressed FCF from Veracruz capex. The IV-base of $368.64 assumes 14% base CAGR (clamped from 14.3%, per the scorer notes) — and the scorer flagged this as needing widening because maintenance capex is uncertain. If beer-segment growth normalizes to 2-3% (matching the reverse-DCF) and wine continues impairing, the realistic IV is closer to $200-225, not $368. At $152.82, the 'margin of safety' shrinks from 60% to 25-30%, which is not a Buffett-grade margin for a consumer-staples business with secular and political risks. Multiple compression to 12x P/E on $9 of normalized EPS = $108 stock. That is a 30% downside scenario.

If I am right, the stock could be worth $95-110 within 2-3 years. The combination of a Mexican-tariff hit, GLP-1-driven category contraction, a Canopy-2.0 capital-allocation mistake from management still in seat, and multiple compression to consumer-staples-with-leverage levels (10-12x P/E) puts the stock at $100 give or take. That is a 30-35% drawdown from here, with the lost decade for shareholders that follows.

Lollapalooza Bias Check

Anchoring. I am anchored to the IV-base of $368.64 and the px/IV ratio of 0.4146. These numbers are deterministic, but they are not God-given — they reflect a base CAGR of 14% which the scorer itself flagged as needing widening. If beer growth normalizes to 4-5% rather than 14%, IV-base could be $220-250, and the 'cheap' stock becomes a 'fair' stock. I should mentally re-anchor on the IV-low of $250.50 as the more defensible base case.

Confirmation bias. I came into this analysis liking the Modelo franchise (it is genuinely a great business), and I have been searching for reasons the price is wrong rather than reasons the price is right. The market has had a year to price in tariffs, GLP-1s, and Hispanic-consumer weakness, and a 60% discount to IV is unusual for a U.S. consumer-staples leader — the efficient-market prior should be that the market sees something I don't. The Canopy investment is a real data point that I want to dismiss.

Authority / social proof. Constellation has been a Bill Ackman / value-investor darling at various points (Pershing Square owned a position, multiple value-investor letters have written it up). I am pattern-matching to 'smart-money is in this stock' which is exactly the kind of social-proof bias Munger warns about. The 13F overlap does not make the thesis right; it just means my peer group is also long.

Recency bias. The 2023 Bud Light gift and the 2024 Modelo #1 dollar-share moment are recent and salient; the 2018 Canopy disaster is old and faded. Recency biases me toward the bull case. I should weight the disaster equally, not less.

Incentive bias (mine, the analyst). I am running a 12-step Buffett-Munger analysis, and the framework rewards finding wonderful businesses at fair prices. There is a soft bias toward producing a Buy rating — that is the satisfying output. I need to be willing to write 'Hold' or 'Too Hard' if the analysis warrants it, and not stretch to 'Buy' for narrative completeness.

Deprival super-reaction. The stock is down ~50% from 2022 highs. Loss-aversion machinery kicks in: 'it must bounce back.' But mean-reversion is not a thesis. The 2022 high may have been the wrong price, not the current price.

Active biases not present here. I do not have a position-commitment bias (no current holding). Authority bias around management is muted (I am skeptical of the Sands family governance). Liking/halo bias around the brand is present but I have flagged it.

Net. The lollapalooza of biases pushes me toward Buy. Adjusting for them, the rating should be Buy-with-eyes-open or Hold, not Strong Buy. I will write 'Buy / medium conviction.'

10-Year Outlook

Same fundamental business model in 10 years? Mostly yes for beer, definitely no for wine. The beer segment will look similar — Modelo, Corona, Pacifico sold in the U.S. through three-tier distribution — but with a meaningful non-alcoholic line, a possible RTD/cocktail extension, and likely 1-2 incremental brands acquired or built. Wine & Spirits will be a fraction of current size, possibly fully divested. The consolidated company in 2036 is essentially a beer-pure-play, which is structurally cleaner.

Customer base larger? Probably modestly larger. Hispanic-American population continues to grow (~1.5%/yr) and Modelo has share-gain runway against domestic premium brands. Offsets: GLP-1 penetration may reach 15-25% of adults by 2036 with 20-30% alcohol-reduction effects in users; Gen-Z lower per-capita drinking persists. Net: customer count flat to +10% over a decade is realistic, not the +30% bulls assume.

Profit per customer higher? Yes. Pricing power of 1-3%/year compounds to 10-30% over a decade; mix shift toward Modelo Especial and away from lower-priced wine improves consolidated margins. Beer-segment margins should expand 200-400 bps from current levels.

Moat wider or narrower? Slightly narrower. The three-tier regulatory moat erodes if direct-to-consumer alcohol delivery laws expand (currently restricted state-by-state). The brand moat strengthens. The 'authenticity' moat is unchanged. Net: roughly the same width, possibly 5-10% narrower at the margin.

Single biggest threat? Mexican tariffs imposed by the U.S. government. Second: GLP-1 secular category contraction. Third: a generational shift toward sobriety that beer marketing cannot reverse.

Confidence assessment. The beer franchise is highly predictable; the political/tariff overlay is genuinely unpredictable; the GLP-1 impact is moderately predictable (probably 5-15% category headwind over a decade). The IV math holds for medium-confidence outcomes but not high. I am comfortable that STZ in 2036 is a recognizable, profitable, cash-generative business — I am not confident enough about the magnitude to call this HIGH.

CONFIDENCE: medium

Position Guidance

• Recommendation: Buy
• Conviction: Medium
• Target buy price: $165 or below (current $152.82 qualifies; aggressive accumulation below $140)
• Target trim price: $300 (above IV-low $250.50, approaching IV-base $368.64; trim aggressively above $350)
• Position sizing: 3-5% starter position; up to 7-8% on weakness below $130; cap at 8% given tariff/GLP-1 tail risks and Sands-family governance discount